home / stock / dsgn / dsgn quote
Last: | $4.47 |
---|---|
Change Percent: | -1.76% |
Open: | $4.47 |
Close: | $4.55 |
High: | $4.55 |
Low: | $4.33 |
Volume: | 48,135 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.47 | $4.47 | $4.55 | $4.55 | $4.33 | 48,135 | 07-17-2024 |
$4.55 | $4.58 | $4.55 | $4.705 | $4.44 | 213,114 | 07-16-2024 |
$4.48 | $4.39 | $4.48 | $4.6 | $4.2993 | 143,881 | 07-15-2024 |
$4.36 | $4.32 | $4.36 | $4.56 | $4.27 | 210,495 | 07-12-2024 |
$4.24 | $3.74 | $4.24 | $4.29 | $3.66 | 205,900 | 07-11-2024 |
$3.62 | $3.45 | $3.62 | $3.66 | $3.45 | 34,164 | 07-10-2024 |
$3.5 | $3.49 | $3.5 | $3.54 | $3.42 | 58,044 | 07-09-2024 |
$3.5 | $3.46 | $3.5 | $3.57 | $3.46 | 93,881 | 07-08-2024 |
$3.42 | $3.17 | $3.42 | $3.44 | $3.15 | 77,061 | 07-05-2024 |
$3.19 | $3.23 | $3.19 | $3.33 | $3.16 | 417,876 | 07-04-2024 |
$3.19 | $3.23 | $3.19 | $3.33 | $3.16 | 417,876 | 07-03-2024 |
$3.2 | $3.25 | $3.2 | $3.4 | $3.17 | 151,139 | 07-02-2024 |
$3.25 | $3.32 | $3.25 | $3.35 | $3.21 | 166,612 | 07-01-2024 |
$3.35 | $3.4 | $3.35 | $3.5 | $3.2375 | 397,800 | 06-28-2024 |
$3.35 | $3.25 | $3.35 | $3.38 | $3.21 | 167,072 | 06-27-2024 |
$3.23 | $3.29 | $3.23 | $3.31 | $3.1695 | 145,840 | 06-26-2024 |
$3.31 | $3.32 | $3.31 | $3.43 | $3.29 | 182,491 | 06-25-2024 |
$3.36 | $3.37 | $3.36 | $3.43 | $3.295 | 193,475 | 06-24-2024 |
$3.38 | $3.32 | $3.38 | $3.42 | $3.32 | 183,126 | 06-21-2024 |
$3.31 | $3.57 | $3.31 | $3.61 | $3.3 | 240,281 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Design Therapeutics Inc. Company Name:
DSGN Stock Symbol:
NASDAQ Market:
Design Therapeutics Inc. Website:
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in H...
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conf...
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) wit...